View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 4, 2020updated 12 May 2020 10:35am

Medable secures financing to accelerate clinical drug development

US-based data-driven clinical trials provider Medable has secured $25m in financing to accelerate clinical drug development with digital technology.

US-based data-driven clinical trials provider Medable has secured $25m in financing to accelerate clinical drug development with digital technology.

Drug development using digital technologies will enable effective new therapies that reach patients faster.

Led by early-stage healthcare and artificial intelligence (AI) investor GSR Ventures, the funding round also involved additional investment from existing investor PPD, bringing Medable’s total capital raised to over $45m.

Funds generated from the financing round will be used to extend product development and partnerships, as well as market adoption for Medable’s decentralised trial platform.

The decentralised trial platform of the company brings together clinical trial participants, research sites, partners and analytics to enable more patient-centric clinical research.

Medable CEO and co-founder Dr Michelle Longmire said: “This is an important milestone for Medable and the industry’s shift to decentralised trials, which are critical to bringing effective therapies to patients faster.

“As we’ve seen with the Covid-19 pandemic, traditional trial processes and timelines are insufficient to meet the global need for clinical research. Decentralised trials can improve access to new therapies and trials for participants, as well as reduce trial timelines.”

Medable is currently working towards reducing clinical trial timelines by 50% and is engaged in the movement to digitise and virtualise clinical trials.

The company’s team has built a modular digital platform-as-a-service, which streamlines clinical trials with direct-to-patient technologies.

Medable noted that the platform is now used by leading biopharmaceutical sponsors and CROs worldwide and has been used for trials in more than 30 countries.

GSR Ventures partner Sunny Kumar said: GSR Ventures said: “The future of medicine is digital, personalised, data-driven and delivered directly to the patient.

“Medable has built a diverse and capable team of technology and biopharma experts, and they have built a comprehensive platform that is well-positioned to meet the market need.”

Last year, the University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare selected digital trials platform provider Medable’s Cloud-based platform to study statin-related adverse events.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena